KB001-A

Humanigen, Inc. · Phase 2 active Biologic

At a glance

Generic name	KB001-A
Sponsor	Humanigen, Inc.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment (PHASE2)
Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa (PHASE1, PHASE2)
Pilot Trial of KB001 in Mechanically-Ventilated Patients Colonized With Pseudomonas Aeruginosa (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

KB001-A CI brief — competitive landscape report
KB001-A updates RSS · CI watch RSS
Humanigen, Inc. portfolio CI